Evolent Health, Inc. EVH
4.71 USD +0.13 (+2.84%)
At closeNov 9, 2026, 4:23 PM EST
4.74 +0.03 +0.64%
After hours · Nov 9, 4:23 PM ET
4.38 Day range 4.84
2.10 52-week range 6.26
- YTD
- +17.75%
- 1 year
- -5.04%
News
seekingalpha.com Evolent Health, Inc. (EVH) Q3 2026 Earnings Call Transcript Evolent Health, Inc. ( EVH ) Q3 2026 Earnings Call November 5, 2026 8:30 AM EST Company Participants Seth Blackley - Co-Founder, CEO & Director Mario Ramos - Chief Financial Officer Conference Call…
marketbeat.com What Evolent Health (EVH) Said on Its Q3 Earnings Call Evolent Health NYSE: EVH raised the lower end of its 2026 adjusted earnings outlook after third-quarter revenue and profitability improved from the preceding quarter, helped by growth in its…
benzinga.com Oppenheimer Maintains Outperform on Evolent Health, Raises Price Target to $7 Oppenheimer analyst Michael Wiederhorn maintains Evolent Health (NYSE:EVH) with a Outperform and raises the price target from $6 to $7.
benzinga.com Needham Maintains Buy on Evolent Health, Raises Price Target to $6 Needham analyst Matthew Shea maintains Evolent Health (NYSE:EVH) with a Buy and raises the price target from $5 to $6.
zacks.com Evolent Health (EVH) Matches Q3 Earnings Estimates Evolent Health (EVH) came out with quarterly earnings of $0.06 per share, in line with the Zacks Consensus Estimate . This compares to earnings of $0.05 per share a year ago.
benzinga.com Evolent Health Q3 2026 Earnings Call Transcript Evolent Health (NYSE:EVH) reported third-quarter financial results on Thursday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to you…- benzinga.com Evolent Health Affirms FY2026 Sales Guidance of $2.600B-$2.700B vs $2.626B Est Evolent Health (NYSE:EVH) affirms FY2026 sales outlook from $2.600 billion-$2.700 billion to $2.600 billion-$2.700 billion vs $2.626 billion estimate.
benzinga.com Evolent Health Q3 Adj. EPS $0.06 Beats $0.05 Estimate, Sales $725.367M Beat $724.186M Estimate Evolent Health (NYSE:EVH) reported quarterly earnings of $0.06 per share which beat the analyst consensus estimate of $0.05 by 20 percent. This is a 20 percent increase over earnings of $0.05 per…
prnewswire.com Evolent Announces Third Quarter 2026 Results WASHINGTON, Nov. 5, 2026 /PRNewswire/ -- Evolent Health, Inc. (NYSE: EVH) ("Evolent" or the "Company"), a company that specializes in better health outcomes for people with complex conditions through…
benzinga.com JP Morgan Maintains Overweight on Evolent Health, Raises Price Target to $6 JP Morgan analyst John Stansel maintains Evolent Health (NYSE:EVH) with a Overweight and raises the price target from $5 to $6.
benzinga.com TD Cowen Maintains Buy on Evolent Health, Raises Price Target to $6 TD Cowen analyst Charles Rhyee maintains Evolent Health (NYSE:EVH) with a Buy and raises the price target from $5 to $6.- benzinga.com Truist Securities Maintains Hold on Evolent Health, Lowers Price Target to $6 Truist Securities analyst Jailendra Singh maintains Evolent Health (NYSE:EVH) with a Hold and lowers the price target from $7 to $6.
- benzinga.com Citigroup Upgrades Evolent Health to Buy, Lowers Price Target to $6 Citigroup analyst Daniel Grosslight upgrades Evolent Health (NYSE:EVH) from Neutral to Buy and lowers the price target from $6.75 to $6.
benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session Gainers P3 Health Partners (NASDAQ:PIII) shares increased by 24.1% to $15.92 during Monday's after-market session. The market value of their outstanding shares is at $38.5 million. As per the press…
benzinga.com Canaccord Genuity Maintains Buy on Evolent Health, Lowers Price Target to $6 Canaccord Genuity analyst Richard Close maintains Evolent Health (NYSE:EVH) with a Buy and lowers the price target from $7 to $6.
benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session Gainers Creative Medical Tech (NASDAQ:CELZ) stock increased by 86.9% to $1.25 during Thursday's pre-market session. The company's market cap stands at $4.3 million. Ensysce Biosciences (NASDAQ:ENSC)…
benzinga.com Evolent Health Raises FY2026 Sales Guidance from $2.400B-$2.600B to $2.600B-$2.700B vs $2.503B Est Evolent Health (NYSE:EVH) raises FY2026 sales outlook from $2.400 billion-$2.600 billion to $2.600 billion-$2.700 billion vs $2.503 billion estimate.
benzinga.com Evolent Health Q2 Adj. EPS $0.02 Beats $(0.02) Estimate, Sales $652.520M Beat $597.997M Estimate Evolent Health (NYSE:EVH) reported quarterly earnings of $0.02 per share which beat the analyst consensus estimate of $(0.02) by 200 percent. This is a 120 percent increase over losses of $(0.10) per…- benzinga.com TD Cowen Maintains Buy on Evolent Health, Lowers Price Target to $5 TD Cowen analyst Charles Rhyee maintains Evolent Health (NYSE:EVH) with a Buy and lowers the price target from $8 to $5.
- benzinga.com Citigroup Downgrades Evolent Health to Neutral, Raises Price Target to $6.75 Citigroup analyst Daniel Grosslight downgrades Evolent Health (NYSE:EVH) from Buy to Neutral and raises the price target from $5.5 to $6.75.
benzinga.com Canaccord Genuity Maintains Buy on Evolent Health, Raises Price Target to $7 Canaccord Genuity analyst Richard Close maintains Evolent Health (NYSE:EVH) with a Buy and raises the price target from $6 to $7.- benzinga.com Truist Securities Downgrades Evolent Health to Hold, Maintains Price Target to $7 Truist Securities analyst Jailendra Singh downgrades Evolent Health (NYSE:EVH) from Buy to Hold and maintains the price target from $7 to $7.
- benzinga.com Truist Securities Maintains Buy on Evolent Health, Raises Price Target to $7 Truist Securities analyst Jailendra Singh maintains Evolent Health (NYSE:EVH) with a Buy and raises the price target from $6 to $7.
benzinga.com Rumble, Agilon Health And Oscar Health Among Stocks Moving Higher On Thursday Stocks had mixed performance on Thursday, Dow Jones up 793 points while Nasdaq down 232 points. Rumble rose after $270M deal.- benzinga.com Citigroup Maintains Buy on Evolent Health, Raises Price Target to $5.5 Citigroup analyst Daniel Grosslight maintains Evolent Health (NYSE:EVH) with a Buy and raises the price target from $4 to $5.5.
- benzinga.com Needham Maintains Buy on Evolent Health, Raises Price Target to $5 Needham analyst Matthew Shea maintains Evolent Health (NYSE:EVH) with a Buy and raises the price target from $4 to $5.
- benzinga.com Evolent Health Affirms FY2026 Sales Guidance of $2.400B-$2.600B vs $2.487B Est. Evolent Health (NYSE:EVH) affirms FY2026 sales outlook from $2.400 billion-$2.600 billion to $2.400 billion-$2.600 billion vs $2.487 billion estimate.
- benzinga.com Evolent Health Q1 Adj. EPS $(0.02) Beats $(0.05) Estimate, Sales $496.246M Miss $534.669M Estimate. Evolent Health (NYSE:EVH) reported quarterly losses of $(0.02) per share which beat the analyst consensus estimate of $(0.05) by 60 percent. This is a 133.33 percent decrease over earnings of $0.06…
benzinga.com XOMA Royalty, Oruka Therapeutics, Repay Holdings And Other Big Stocks Moving Higher On Monday U.S. stocks were lower, Dow Jones fell 0.1% on Monday. XOMA shares rose on Ligand's plans to acquire XOMA for $39.00/share. Other big gainers: MANE, ORKA, OGN, XE, PLBL, SLS, ANAB, EVH, IHRT, RPAY,…- benzinga.com Oppenheimer Maintains Outperform on Evolent Health, Lowers Price Target to $6 Oppenheimer analyst Michael Wiederhorn maintains Evolent Health (NYSE:EVH) with a Outperform and lowers the price target from $12 to $6.
- benzinga.com Citigroup Maintains Buy on Evolent Health, Lowers Price Target to $4 Citigroup analyst Daniel Grosslight maintains Evolent Health (NYSE:EVH) with a Buy and lowers the price target from $6 to $4.
- benzinga.com UBS Maintains Buy on Evolent Health, Lowers Price Target to $5 UBS analyst Kevin Caliendo maintains Evolent Health (NYSE:EVH) with a Buy and lowers the price target from $10 to $5.
- benzinga.com Truist Securities Maintains Buy on Evolent Health, Lowers Price Target to $6 Truist Securities analyst Jailendra Singh maintains Evolent Health (NYSE:EVH) with a Buy and lowers the price target from $10 to $6.
- benzinga.com Needham Maintains Buy on Evolent Health, Lowers Price Target to $4 Needham analyst Matthew Shea maintains Evolent Health (NYSE:EVH) with a Buy and lowers the price target from $15 to $4.
- benzinga.com RBC Capital Maintains Sector Perform on Evolent Health, Lowers Price Target to $3 RBC Capital analyst Ryan Halsted maintains Evolent Health (NYSE:EVH) with a Sector Perform and lowers the price target from $5 to $3.
benzinga.com Evolent Health Stock: A Deep Dive Into Analyst Perspectives (4 Ratings) 
benzinga.com This First Solar Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday - benzinga.com BTIG Maintains Buy on Evolent Health, Lowers Price Target to $8 BTIG analyst David Larsen maintains Evolent Health (NYSE:EVH) with a Buy and lowers the price target from $10 to $8.
- benzinga.com Evolent Health Q4 Adj. EPS $0.08 Beats $0.06 Estimate, Sales $468.719M Beat $468.701M Estimate Evolent Health (NYSE:EVH) reported quarterly earnings of $0.08 per share which beat the analyst consensus estimate of $0.06 by 37.93 percent. This is a 500 percent increase over losses of $(0.02) per…
benzinga.com Earnings Scheduled For February 24, 2026 
benzinga.com Deep Dive Into Evolent Health Stock: Analyst Perspectives (11 Ratings) - benzinga.com BTIG Maintains Buy on Evolent Health, Lowers Price Target to $10 BTIG analyst David Larsen maintains Evolent Health (NYSE:EVH) with a Buy and lowers the price target from $16 to $10.
- benzinga.com Citigroup Maintains Buy on Evolent Health, Lowers Price Target to $6 Citigroup analyst Daniel Grosslight maintains Evolent Health (NYSE:EVH) with a Buy and lowers the price target from $9.5 to $6.
- benzinga.com The Analyst Verdict: Evolent Health In The Eyes Of 9 Experts
- benzinga.com Citizens Maintains Market Outperform on Evolent Health, Lowers Price Target to $10 Citizens analyst Constantine Davides maintains Evolent Health (NYSE:EVH) with a Market Outperform and lowers the price target from $11 to $10.
- benzinga.com Citigroup Maintains Buy on Evolent Health, Lowers Price Target to $9.5 Citigroup analyst Daniel Grosslight maintains Evolent Health (NYSE:EVH) with a Buy and lowers the price target from $11.5 to $9.5.
- benzinga.com JP Morgan Maintains Overweight on Evolent Health, Lowers Price Target to $7 JP Morgan analyst Anne Samuel maintains Evolent Health (NYSE:EVH) with a Overweight and lowers the price target from $13 to $7.
- benzinga.com Canaccord Genuity Maintains Buy on Evolent Health, Lowers Price Target to $9 Canaccord Genuity analyst Richard Close maintains Evolent Health (NYSE:EVH) with a Buy and lowers the price target from $16 to $9.
- benzinga.com BMO Capital Initiates Coverage On Evolent Health with Outperform Rating, Announces Price Target of $7 BMO Capital analyst Sean Dodge initiates coverage on Evolent Health (NYSE:EVH) with a Outperform rating and announces Price Target of $7.
- benzinga.com Oppenheimer Maintains Outperform on Evolent Health, Lowers Price Target to $12 Oppenheimer analyst Michael Wiederhorn maintains Evolent Health (NYSE:EVH) with a Outperform and lowers the price target from $18 to $12.